Description:

Size: 100ul

Catalog no.: bs-2341R-A555

Price: 380 EUR

Product details

Modification Site

None

Crossreactivity

Others

French translation

anticorps

Tested applications

IF(IHC-P)

Cross-reactive species details

PGF2 Alpha

Clonality

Polyclonal

Target Antigen

PGF2 alpha

Modification

Unmodified

Concentration

1ug per 1ul

Excitation emission

553nm/568nm

Conjugated with

ALEXA FLUOR® 555

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR 555

Source

KLH conjugated to PGF2 Alpha

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-PGF2 alpha PAb ALEXA FLUOR 555

Specificity

This is a highly specific antibody against PGF2 alpha.

Long name

PGF2 alpha Polyclonal Antibody, ALEXA FLUOR 555 Conjugated

Description

The Anti-PGF2 alpha is a α- or alpha protein sometimes glycoprotein present in blood.

Synonyms

Prostaglandin F2 Alpha; PGF2 Alpha; 5Z,9α,11α,13E,15S-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2α−Tris.

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.Very high photo stable ALEXA conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2α and luteal oxytocin is responsible for completion of luteolysis.Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.